Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

18 Nov '2020
Olema Oncology Announces Pricing of Initial Public Offering
SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial

Events & Presentations

SEC Filings

Filing date Description Form

Filing by person(s) reporting owned shares of common stock in a public company >5%

 SC 13D

Statement of changes in beneficial ownership of securities

 4

Statement of changes in beneficial ownership of securities

 4